Translations:Hyperlipidemia/9/en

! Defect

 ! Increased lipoprotein
 ! Main symptoms
 ! Treatment
 ! Serum appearance
 ! Estimated prevalence

|-

 !rowspan=3| Type I
 ! a
 |  238600
 | Buerger-Gruetz syndrome or familial hyperchylomicronemia
 | Decreased lipoprotein lipase (LPL)
 |rowspan=3| Chylomicrons
 |rowspan=3| Acute pancreatitis, lipemia retinalis, eruptive skin xanthomas, hepatosplenomegaly
 |rowspan=3| Diet control
 |rowspan=3| Creamy top layer
 |rowspan=3| One in 1,000,000

|-

 ! b
 |  207750
 | Familial apoprotein CII deficiency
 | Altered ApoC2

|-

 ! c
 |  118830
 |
 | LPL inhibitor in blood

|-

 !rowspan=2| Type II
 ! a
 |  143890
 | Familial hypercholesterolemia
 | LDL receptor deficiency
 | LDL
 | Xanthelasma, arcus senilis, tendon xanthomas
 | Bile acid sequestrants, statins, niacin
 | Clear
 | One in 500 for heterozygotes

|-

 ! b
 |  144250
 | Familial combined hyperlipidemia
 | Decreased LDL receptor and increased ApoB
 | LDL and VLDL
 |
 | Statins, niacin, fibrate
 | Turbid
 | One in 100

|-

 !colspan=2| Type III
 |  107741
 | Familial dysbetalipoproteinemia
 | Defect in Apo E 2 synthesis
 | IDL
 | Tuberoeruptive xanthomas and palmar xanthomas
 | Fibrate, statins
 | Turbid
 | One in 10,000

|-

 !colspan=2| Type IV
 |  144600
 | Familial hypertriglyceridemia
 | Increased VLDL production and decreased elimination
 | VLDL
 |Can cause pancreatitis at high triglyceride levels
 | Fibrate, niacin, statins
 | Turbid
 | One in 100

|-

 !colspan=2| Type V
 |  144650
 |
 | Increased VLDL production and decreased LPL
 | VLDL and chylomicrons
 |
 | Niacin, fibrate
 | Creamy top layer and turbid bottom
 |

|}